Martin Axon, CFFOH, CMIOSH, SafeBridge Europe, Ltd. - Qepler Summits And Conferences

Martin Axon, CFFOH, CMIOSH

Principal Occupational Hygienist
SafeBridge Europe, Ltd.
Stevenage, United Kingdom
SafeBridge, developer of the Potent Compound Safety Triangle™, provides industrial hygiene, toxicology, and safety services to the pharmaceutical, biotechnology, and fine chemicals industries.

Martin Axon is Principal Occupational Hygienist for SafeBridge Europe and is a Chartered Fellow of the Faculty of Occupational Hygiene; he has degrees in Industrial Chemistry and Environmental Pollution Science. He has over 25 years of experience working in the pharmaceutical industry in the UK and internationally, where, as an occupational hygienist for primary and secondary sites, he provided support for potent pharmaceutical product manufacture. During mid-career he was Course Director for a postgraduate programme in Occupational Hygiene, Health and Safety, at London South Bank University.

Martin joined SafeBridge in 2005. His current role includes managing SafeBridge’s services in Europe and advising clients on the safe handling of potent pharmaceutical compounds in a range of environments, from laboratory scale through to secondary manufacture.

Related Sessions:

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 1: Wednesday, 19 February 2020
CASE STUDY: Assessing Containment Performance of Continuous Table Coating Equipment.
  • Operation of the GEA tablet coater.
  • Working with GEA to make preparations for the project.
  • Assessments during operation and during disassembly/cleaning.
  • Outcomes: suitability of the equipment to process tablets containing potent API.
View Details

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 2: Thursday, 20 February 2020
CASE STUDY: Evaluating a CMO’s Overall Ability to Safely Handle Potent APIs.
  • Management and resource.
  • Evaluating the hazard.
  • Controlling exposure risks.
  • Verifying controls.
  • Design of the facility from an exposure control perspective.
  • Employee understanding of API safety.
View Details

3rd Annual Highly Potent
APIs Summit 2023

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 23 Feb 2023
  • Virtual,
  • Pharma
Day 2: Friday, 24 February 2023
CASE STUDY: To Be Announced
View Details
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookies Policy.